BRPI0811864A2 - Derivados de ácido cistéico de peptídeos antivirais - Google Patents

Derivados de ácido cistéico de peptídeos antivirais

Info

Publication number
BRPI0811864A2
BRPI0811864A2 BRPI0811864-7A2A BRPI0811864A BRPI0811864A2 BR PI0811864 A2 BRPI0811864 A2 BR PI0811864A2 BR PI0811864 A BRPI0811864 A BR PI0811864A BR PI0811864 A2 BRPI0811864 A2 BR PI0811864A2
Authority
BR
Brazil
Prior art keywords
cytisic
antivial
peptides
acid derivatives
derivatives
Prior art date
Application number
BRPI0811864-7A2A
Other languages
English (en)
Inventor
Omar Quraishi
Martin Robitaille
Dominique P Bridon
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Publication of BRPI0811864A2 publication Critical patent/BRPI0811864A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0811864-7A2A 2007-05-16 2008-05-16 Derivados de ácido cistéico de peptídeos antivirais BRPI0811864A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93838007P 2007-05-16 2007-05-16
US93839407P 2007-05-16 2007-05-16
PCT/US2008/064010 WO2008144584A2 (en) 2007-05-16 2008-05-16 Cysteic acid derivatives of anti-viral peptides

Publications (1)

Publication Number Publication Date
BRPI0811864A2 true BRPI0811864A2 (pt) 2014-11-18

Family

ID=39925035

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811864-7A2A BRPI0811864A2 (pt) 2007-05-16 2008-05-16 Derivados de ácido cistéico de peptídeos antivirais

Country Status (8)

Country Link
US (1) US20090088377A1 (pt)
EP (1) EP2147016A2 (pt)
JP (1) JP2010527376A (pt)
CN (1) CN101687911A (pt)
AU (1) AU2008254767A1 (pt)
BR (1) BRPI0811864A2 (pt)
CA (1) CA2687700A1 (pt)
WO (1) WO2008144584A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
MX346362B (es) * 2009-11-10 2017-03-15 Allegro Pharmaceuticals Inc * Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.
WO2012154894A2 (en) 2011-05-09 2012-11-15 Allegro Pharmaceuticals, Inc. Integrin receptor antagonists and their methods of use
WO2013127288A1 (zh) * 2012-02-27 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 抗hiv-1多肽及其用途
CA2927126A1 (en) 2013-10-13 2015-04-16 The Board Of Trustees Of The University Of Arkansas Human papilloma virus therapeutic vaccine
CN106163539A (zh) * 2014-01-28 2016-11-23 人口委员会股份有限公司 用于预防性传播感染的组合产品
CN110551179B (zh) * 2018-05-31 2022-03-15 中国科学院微生物研究所 一种经修饰的抗hiv多肽及其制备方法和用途
JP2022551813A (ja) * 2019-09-04 2022-12-14 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 麻疹に対する併用抗ウイルス療法
WO2021222759A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Albumin drug conjugates and use thereof for the treatment of cancer
GB202009007D0 (en) * 2020-06-12 2020-07-29 Univ Bath Modulators of tight junction permeability
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU688733B2 (en) * 1992-07-20 1998-03-19 Duke University Compounds which inhibit HIV replication
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
JP3871713B2 (ja) * 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
KR20020002354A (ko) * 1998-10-13 2002-01-09 추후제출 안정화된 생활성 펩티드 및 이들을 동정, 합성 및이용하는 방법
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
BR0010757A (pt) * 1999-05-17 2002-02-19 Conjuchem Inc Inibidores de peptìdeo de fusão de longa duração de infecção viral
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
DK1479691T3 (da) * 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
CA2564031A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target

Also Published As

Publication number Publication date
US20090088377A1 (en) 2009-04-02
CA2687700A1 (en) 2008-11-27
WO2008144584A2 (en) 2008-11-27
CN101687911A (zh) 2010-03-31
JP2010527376A (ja) 2010-08-12
WO2008144584A3 (en) 2009-01-22
AU2008254767A1 (en) 2008-11-27
EP2147016A2 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
EP2192109A4 (en) Bicyclic -amino acid derivative
DK3118221T3 (da) Proteiner
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
DE602009000580D1 (de) Endoskopsystem
BRPI0919447A2 (pt) derivados do ácido 1-amino-2-ciclobutiletilborônico
EP2226315A4 (en) 2-aminoquinazoline DERIVATIVE
EP2215246A4 (en) PROTEIN SCAFFOLDS
EP2344029A4 (en) Electrode system
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0911743A2 (pt) "peptídeo"
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0814971A2 (pt) Proteína
BRPI0821258A2 (pt) Derivados de ciclopropilamina
BRPI0806538A2 (pt) Derivados de glicinamida de espiropiperidina
BRPI0814763A2 (pt) Peptídeos imunomoduladores
BRPI0922652A2 (pt) Derivados de quinazolinamida
BRPI0913234A2 (pt) derivados de tiazolilpiperidina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]